Mortality benefit with antifibrotics in idiopathic pulmonary fibrosis: real world evidence or bias?
- PMID: 33737380
- DOI: 10.1183/13993003.04562-2020
Mortality benefit with antifibrotics in idiopathic pulmonary fibrosis: real world evidence or bias?
Conflict of interest statement
Conflict of interest: S. Suissa attended scientific advisory committee meetings for Atara, Merck, Pfizer and Seqirus, and received speaking fees from Boehringer Ingelheim and Novartis. Conflict of interest: D. Assayag received consulting fees from Hoffman-La Roche Canada and Boehringer Ingelheim Canada.
Comment in
-
Reply: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis.Eur Respir J. 2021 Mar 18;57(3):2100283. doi: 10.1183/13993003.00283-2021. Print 2021 Mar. Eur Respir J. 2021. PMID: 33737382 No abstract available.
Comment on
-
Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.Eur Respir J. 2020 Aug 13;56(2):1902279. doi: 10.1183/13993003.02279-2019. Print 2020 Aug. Eur Respir J. 2020. PMID: 32381492
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources